This buy now, pay later stock can keep running after stellar month, Bank of America says

Affirm posted strong fiscal Q3 results, with revenue of $1.04 billion versus $995.3 million expected and adjusted operating income of $281 million versus $248.9 million consensus. Bank of America raised its price target to $88 from $82 and reiterated a buy rating, citing disciplined underwriting, healthy consumer demand, and improving monetization trends. Affirm also guided fiscal 2025 revenue to $4.175 billion-$4.205 billion, above the $4.14 billion Street estimate, even after the stock fell 5% on Friday.

Analysis

The market is likely pricing the wrong variable: not quarterly execution, but the durability of Affirm’s funding and loss curves into the next 2-3 quarters. A better-than-feared print with a softer stock reaction often signals positioning was already crowded on the long side, so the immediate upside is more likely to come from estimate revisions than from multiple expansion. The setup favors a “buy the dip, but only on a clean reset” dynamic because the next catalyst window is the investor forum, where management can re-anchor medium-term take-rate and credit-loss assumptions.

Competitive dynamics are subtly improving for the best-underwritten BNPL names. In a tighter credit environment, merchants and consumers tend to concentrate toward providers that can keep approvals high without blowing out losses, which can widen share gaps even if category growth is only mid-teens. The second-order effect is that lenders with weaker underwriting or higher funding costs may have to pull back marketing or tighten terms, which helps Affirm’s unit economics more than headline GMV growth suggests.

The main bear case is not macro deterioration per se, but a normalization in sentiment after a very fast run. With the stock up sharply in a month, good news may be largely in the price, and any hint that funding spreads are drifting wider or that consumer credit trends lag revenue growth could trigger a fast de-rating. On a 1-3 month horizon, the stock is vulnerable to a “show me” phase; over 6-12 months, the debate shifts to whether monetization can outgrow credit losses and justify sustained premium valuation.

Consensus is missing that this is less a pure AI-style rerating story and more a balance-sheet-resilience story disguised as growth. If underwriting remains disciplined, earnings power can compound even in a slower macro backdrop, but if the market starts to believe the improvement is cyclical rather than structural, upside compresses quickly. The asymmetry is better expressed through defined-risk structures than outright beta chasing after a month-long squeeze.

Key Decisions for Investors

• Initiate a tactical long in AFRM on a 1-2 week pullback or after the 5/12 Investor Forum, targeting a 10-15% rebound; stop if management commentary implies credit losses or funding costs are trending worse than expected.
• Prefer an AFRM call spread over outright stock for the next 6-8 weeks (e.g., 1-month to 3-month tenor) to capture a post-forum repricing while limiting downside if the name enters a consolidation phase.
• Pair trade: long AFRM / short a weaker fintech or consumer-lending peer with more rate-sensitive funding or lower underwriting quality over 2-3 months, to isolate relative credit-quality outperformance.
• If already long AFRM, trim 20-30% into strength after the investor forum unless guidance is raised again; the stock has already de-risked a lot of good news and is vulnerable to multiple compression.
• Avoid chasing BAC on the headline; this is a stock-specific underwriting and positioning call, not a bank-wide read-through.